Cell and Transport Physiology

Regulation of Renal Sodium Transporters during Severe Inflammation

Christoph Schmidt, Klaus Höcherl, Frank Schweda, Armin Kurtz and Michael Bucher
JASN April 2007, 18 (4) 1072-1083; DOI: https://doi.org/10.1681/ASN.2006050454

Abstract

Sepsis-associated acute renal failure is characterized by decreased GFR and tubular dysfunction. The pathogenesis of endotoxemic tubular dysfunction with failure in urine concentration and increased fractional sodium excretion is poorly understood. This study investigated the regulation of renal sodium transporters during severe inflammation in vivo and in vitro. Injection of high-dosage LPS reduced BP and GFR, increased fractional sodium excretion, and strongly decreased the expression of Na+/H+-exchanger, renal outer medullary potassium channel, Na+-K+-2Cl− co-transporter, epithelial sodium channel, and Na+/K+-ATPase in mice. Also, injection of TNF-α, IL-1β, or IFN-γ decreased renal function and expression of renal sodium transporters. LPS-induced downregulation of sodium transporters was not affected in cytokine-knockout mice. However, supplementary glucocorticoid treatment, which inhibited LPS-induced increase of tissue cytokine concentrations, attenuated LPS-induced renal dysfunction and downregulation of tubular sodium transporters. Injection of low-dosage LPS increased renal tissue cytokines and downregulated renal sodium transporters without arterial hypotension. In vitro, in cortical collecting duct cells, cytokines also decreased expression of renal outer medullary potassium channel, epithelial sodium channel, and Na+/K+-ATPase. Renal hypoperfusion by renal artery clipping did not influence renal sodium transporter expression, in contrast to renal ischemia-reperfusion injury, which depressed transporter expression. These findings demonstrate downregulation of renal sodium transporters that likely accounts for tubular dysfunction during inflammation. These data suggest that alteration of renal sodium transporters during LPS-induced acute renal failure is mediated by cytokines rather than renal ischemia. However, in a complex in vivo model of severe inflammation, the possible presence and influence of renal hypoperfusion and reperfusion on the expression of renal sodium transporters cannot be completely excluded.

Sepsis is the most common cause of acute renal failure (ARF) in the intensive care unit (1). ARF is present in 20% of patients with severe sepsis and 50% of patients with septic shock (2) and is clinically defined as a deterioration of GFR and tubular function. Little is known about the pathophysiology of endotoxemic tubular dysfunction with failure in urine concentration and increased fractional sodium excretion.

Urine concentration requires establishment and maintenance of a hypertonic medullary interstitium, which depends on the NaCl reabsorption (3). The Na+/H+-exchanger (NHE3) and the functional unit of ROMK and Na+-K+-2Cl− co-transporter (NKCC2) are key components that are responsible for sodium reabsorption by the thick ascending limb (3,4). ROMK, also located in the cortical collecting duct (CCD), is responsible for recycling K+ across the apical membrane, which is critical for continuous sodium uptake by NKCC2 (5–8). In the collecting duct, the vasopressin-regulated epithelial sodium channel (ENaC), composed of three homologous subunits (9,10), accounts for the fine adjustment of the sodium reabsorption. The Na+/K+-ATPase in the basolateral membrane is essential for the efficient sodium reabsorption along the whole nephron.

Findings that endotoxemia diminishes expression of renal V2 receptors and aquaporin-2 (11) directed our interest toward the regulation of tubular sodium transporters during experimental sepsis. We hypothesized that endotoxemia downregulates tubular sodium transporters. On the basis of our previous findings that proinflammatory cytokines downregulate several vasoconstrictive receptors in renal tissue (12–15), we assumed that cytokines affect the expression of renal sodium transporters.

To test our hypotheses, we performed in vivo experiments with (1) mice that were administered an injection of LPS as a model for severe experimental Gram-negative sepsis; (2) mice that were administered injections the cytokines TNF-α, IL-1β, or IFN-γ; (3) knockout mice that had a deficiency for TNF-α, IL-1 receptor-1 (IL-1R1), or IFN-γ and were administered an injection of LPS; (4) mice that did or did not have glucocorticoid pretreatment, which attenuates LPS-induced cytokine production (16–18) and were administered an injection of LPS; (5) mice that were administered an injection of low-dosage LPS using as a model of inflammation without systemic hypotension and renal ischemia; (6) mice with renal artery clipping to reduce renocortical flux to 40% of controls to imitate LPS-induced renal hypoperfusion (19); and (7) mice with renal ischemia-reperfusion injury by complete renal artery occlusion followed by reperfusion. In addition, we investigated the regulation of renal sodium transporters during inflammatory conditions in vitro using murine CCD cells.

Materials and Methods

Animals

All animal experiments were performed according to National Institutes of Health Guide for the Care and Use of Laboratory Animals. Male mice (20 to 25 g) with deficiencies for TNF-α (B6.129S6-Tnftm1Gk1), IL-1R1 (B6.129S7-IL1r1tm1Imx), IFN-γ (B6.129S7-Ifngtm1Ts) and their wild-type strains B6129SF2/J and C57BL/6J, respectively, were purchased from the Jackson Laboratory (Bar Harbor, ME).

Experimental Inflammation

Wild-type mice received NaCl (control) or LPS (Escherichia coli, serotype 0111:B4; Sigma, St. Louis, MO; 10 mg/kg) intraperitoneally and were killed 6, 12, and 24 h (n = 6 per group) after LPS injection and after determination of hemodynamic and renal parameters. Wild-type and cytokine knockout mice received NaCl (control) or LPS 10 mg/kg intraperitoneally (n = 6 per group) and were killed 12 h after injection, the point of time with the strongest effect. Wild-type mice were additionally treated with NaCl (control), TNF-α, IL-1β, IFN-γ (1 μg/g; PeproTech, London, UK), or the combination of TNF-α plus IL-1β or low-dosage LPS (1 and 5 mg/kg) intraperitoneally and were killed 12 h after injection (n = 6 per group). In addition, wild-type mice (n = 6 per group) that received both a single high dosage of dexamethasone alone (10 mg/kg, intraperitoneally) and dexamethasone 2 h before LPS injection were investigated. The dosage of LPS, cytokines, and dexamethasone was chosen from data that were taken from the literature (12,15,20–24).

Renal Hypoperfusion

For induction of renal hypoperfusion, left renal arteries of mice (n = 6 per group) were clipped with 0.11-mm ID silver clips, and mice were killed 6, 12, and 24 h thereafter. The internal diameter of the renal clip was adjusted to reduce the renocortical flux to approximately 40% of the prestenotic level to ensure comparability with septic conditions (19).

Renal Ischemia-Reperfusion Injury

For induction of renal ischemia-reperfusion injury, renal arteries of mice (n = 6 per group) were totally occluded for 30 min with microaneurysm clamps followed by reperfusion. In sham controls, left renal arteries were only touched with forceps.

Measurement of Mean Arterial Pressure and Renal and Blood Parameters

Mice were anesthetized with Sevoflurane, using a Trajan 808 (Dräger, Lübeck, Germany) 6, 12, or 24 h after injection. The right femoral artery was cannulated for continuous monitoring of mean arterial pressure (MAP) and heart rate (Siemens SC 9000, Munich, Germany). The left femoral vein was cannulated for maintenance infusion and the bladder for collecting urine. FITC-inulin (0.5%; Sigma) was added to the infusion for determination of GFR. Plasma and urine FITC-inulin concentrations were measured after an equilibration period of 30 min every 30 min for 2 h and averaged for calculation of inulin clearance. FITC-inulin in plasma and urine samples was measured using a spectrofluorometer (Shimadzu, Columbia, MD). Needle laser Doppler probes (Transonic, Ithaca, NY) were inserted into the renal cortex connected to laser Doppler flowmeters (BLF 21), and renocortical tissue perfusion was measured before and 6, 12, and 24 h after renal artery clipping. Measurement of blood parameters was performed on a Rapidpoint 405 (Bayer, Leverkusen, Germany). Urinary sodium concentration was measured by standard flame photometry (Eppendorf, Hamburg, Germany) adapted to small samples (25).

Cell Culture

Murine CCD cells (M1 cell line) that expressed ROMK, ENaC, and Na+/K+-ATPase transporters (25) were a gift from Dr. R. Schreiber (Department of Physiology, University of Regensburg). Cells were incubated for 12 h with (1) serum-free medium (control); (2) IL-1β (100 ng/ml); (3) TNF-α (100 ng/ml); (4) IFN-γ (100 ng/ml); and (5) a mixture of TNF-α, IL-1β, and IFN-γ (100 ng/ml each). Murine recombinant cytokines were used for the experiments from PeproTech, and the dosage was chosen from published data (12–15).

mRNA Extraction and Real-Time PCR Analysis

Total RNA from tissues and cells was extracted and reverse-transcribed, and real-time PCR was carried out using the LightCycler system (Roche, Basel, Switzerland) as described (15). Each primer set (Table 1) was checked using a BLAST search to ascertain that the sequences were unique for each transporter. β-Actin was used as reference gene.

View this table:
Table 1.

Primer set for sodium transporter analysis by real-time PCRa

Protein Preparation

Kidneys were homogenized in ice-cold homogenization buffer in the presence of protease inhibitors followed by centrifugation with 500 × g for 15 min at 4°C. The resultant supernatant was centrifuged at 20,000 × g for 30 min at 4°C. The resultant supernatant was used for determination of tissue cytokine concentration, and the resultant pellet was reconstituted in blotting buffer and used for Western blotting.

Tissue Concentrations of Cytokines

Tissue concentrations of TNF-α, IL-1β, and IFN-γ were determined using ELISA kits (R&D Systems, Minneapolis, MN) and set into proportion to total protein.

Western Blot

Protein samples (40 μg) were electrophoretically separated on a 10% polyacrylamide gel and transferred to nitrocellulose membrane, which was blocked overnight in 5% nonfat dry milk diluted in Tris-buffered saline with 0.1% Tween-20, and then incubated for 1 h at room temperature with rabbit polyclonal antibodies against ROMK (Alomone, Jerusalem, Israel; 1:500), NHE3, ENaC (Chemicon, Temecula, CA; 1:500 each), Na+/K+-ATPase α1 (Upstate, Chicago, IL, 1:1000), and β-actin (Sigma; 1:5000). After washing, the membrane was incubated for 2 h with secondary antibodies (Santa Cruz Biotechnology, Santa Cruz, CA; 1:2000; ENaC 1:1000, β-actin 1:5000) and subjected to a chemiluminescence detection system. Quantitative assessment of bands was performed densitometrically.

Statistical Analyses

Data were analyzed by ANOVA with multiple comparisons followed by the t test with Bonferroni adjustment. P < 0.05 was considered significant.

Results

Hemodynamic and Blood Parameters

MAP was 74.3 ± 1.6 mmHg in the control group and decreased to 68 and 64% of control 12 and 24 h after LPS injection, respectively. The heart rate of septic mice was significantly higher after LPS injection compared with the control group. Hemoglobin and hematocrit values showed no differences between control and septic groups, whereas plasma sodium increased 12 and 24 h after LPS administration.

IL-1β also led to tachycardia and arterial hypotension with hypernatremia. Injection of only dexamethasone did not influence hemodynamic and blood parameters in wild-type mice 6, 12, or 24 h after injection compared with control (data not shown). Treatment of LPS plus dexamethasone attenuated LPS-induced arterial hypotension in comparison with sole LPS treatment after 12 and 24 h (Table 2).

View this table:
Table 2.

Effect of LPS (10 mg/kg intraperitoneally) without or with dexamethasone (10 mg/kg intraperitoneally) and IL-1β (1 μg/g intraperitoneally) on hemodynamic, blood, and renal parametersa

Renal Parameters

GFR was lower in mice that were administered injections of LPS, and urine flow decreased to 52 and 48% of control 12 and 24 h after injection, respectively. Urinary sodium excretion decreased significantly and fractional sodium excretion was 2.4 and 4.3 times higher in LPS-treated mice compared with control level 12 and 24 h after LPS treatment, respectively. Tubular sodium reabsorption in the mice that were administered injections of LPS was considerably lower than in the control group, decreasing to 29 and 15% of control 12 and 24 h after sepsis-induction, respectively (Table 2).

Twelve hours after injection of IL-1β, renal function of these mice was restricted comparable to mice that were administered injections of LPS. Injection of only dexamethasone showed no relevant changes in functional renal parameters in wild-type mice 6, 12, and 24 h after injection compared with controls (data not shown). Treatment of mice that were administered injections of LPS with dexamethasone attenuated renal injury as indicated by a higher GFR, a higher tubular sodium reabsorption, and a reduced fractional sodium excretion compared with sole LPS injection.

Effect of LPS on Renal Sodium Transporter Expression

ROMK mRNA was downregulated to 5, 5, and 54% of control and NKCC2 mRNA decreased to 41, 18 and 33% of control 6, 12, and 24 h after LPS injection, respectively. ENaC mRNA levels showed a concomitant fall of all three subunits to approximately 75, approximately 55, and approximately 80% of control 6, 12, and 24 h after LPS administration, respectively. In accordance, Na+/K+-ATPase and NHE3 mRNA decreased to approximately 40% of control level 6, 12, and 24 h after LPS injection, respectively (Figure 1).

Figure 1.
Figure 1.

Effect of LPS (10 mg/kg), dexamethasone (10 mg/kg), and the combination of both on renal outer medullary potassium channel (ROMK), Na+-K+-2Cl− co-transporter (NKCC2), epithelial sodium channel (ENaC), Na+/K+-ATPase α1, and Na+/H+-exchanger (NHE3) mRNA in the kidney 6, 12, and 24 h after intraperitoneal injection. Values are related to signals that were obtained for β-actin mRNA and given as percentage of vehicle control. Data are means ± SEM of six mice per group. *P < 0.05 versus control; #P < 0.05 versus LPS.

Figure 2 demonstrates protein expression of ROMK, NHE3, Na+/K+-ATPase, and ENaC as determined by Western blot analysis. The decline of ROMK mRNA abundance was paralleled by a decrease of ROMK protein. NHE3 protein fell to 69 and 41% of control 12 and 24 h after sepsis induction, respectively. Western blot of Na+/K+-ATPase and ENaC-α and -β decreased to approximately 60% of control as well as ENaC-γ to approximately 50% of control 12 and 24 h after sepsis induction, respectively.

Figure 2.
Figure 2.

Effect of LPS (10 mg/kg) on ROMK, ENaC, Na+/K+-ATPase α1, and NHE3 protein in the kidney 6, 12, and 24 h after injection. Representative immunoblot of ROMK; ENaC-α, -β, and -γ; Na+/K+-ATPase; and NHE3 protein. The anti-ROMK antibody recognized a band of 97 kD, and anti-NHE3 antibody and anti–ENaC-β and anti–ENaC-γ antibody recognized a band of 90 kD. The anti–Na+/K+-ATPase antibody detected a band of 110 kD and anti–ENaC-α bands of 83 and 90 kD. Values are related to signals that were obtained for β-actin protein and given as percentage of vehicle control. Data are means ± SEM of six mice per group. *P < 0.05 versus vehicle control.

Effect of Cytokines on Renal Sodium Transporter Expression

For further characterization of the mechanisms along which tubular sodium transporters could be downregulated during endotoxemia, renal gene expression in mice that were administered injections of TNF-α, IL-1β, and IFN-γ was examined, because these proinflammatory cytokines are known to be abundantly generated mediators during sepsis (26). mRNA of all tubular sodium transporters was strongly depressed after injection of TNF-α or IL-1β and decreased especially after the combination of both to mRNA levels that were comparable with those after LPS injection. IFN-γ also downregulated ROMK, ENaC-γ, Na+/K+-ATPase, and NHE3 mRNA (Figure 3).

Figure 3.
Figure 3.

Effect of LPS (10 mg/kg) and proinflammatory cytokines on ROMK, NKCC2, ENaC, Na+/K+-ATPase, and NHE3 mRNA in the kidney 12 h after injection. Values are related to signals that were obtained for β-actin mRNA and given as percentage of vehicle control. Data are means ± SEM of six mice per group. *P < 0.05 versus vehicle control.

Effect of LPS on Sodium Transporter Expression in Cytokine Knockout Mice

To investigate whether LPS-induced downregulation of renal sodium transporter expression could be inhibited by omission of single cytokine effects, we measured mRNA levels of sodium transporters in LPS-treated knockout mice with a deficiency for TNF-α, IL-1R1, or IFN-γ and compared the effect with the impact in their wild-type control strain. Cytokine-knockout and wild-type mice that were administered injections of NaCl revealed comparable sodium transporter mRNA levels (data not shown). Twelve hours after LPS injection, mRNA levels of all tubular sodium transporters were depressed and the downregulative effect of LPS on renal sodium transporters could not be diminished in any knockout species (Figure 4).

Figure 4.
Figure 4.

Effect of LPS (10 mg/kg) on renal ROMK, NKCC2, ENaC, Na+/K+-ATPase, and NHE3 mRNA in cytokine-knockout mice 12 h after injection. Values are related to signals that were obtained for β-actin mRNA and given as percentage of vehicle control. Data are means ± SEM of six mice per group. *P < 0.05 versus vehicle control.

Effect of Dexamethasone on Sodium Transporter Expression in LPS-Treated Mice

Because absence of a single cytokine effect had no effect on LPS-induced downregulation of renal sodium transporters, mice were additionally treated with dexamethasone (10 mg/kg, intraperitoneally). As shown in Table 3, concomitant treatment with dexamethasone markedly attenuated renal tissue cytokine concentration after LPS injection. Therefore, we used dexamethasone treatment as a model to investigate the impact of a diminished action of more than one single cytokine on sodium transporter gene expression.

View this table:
Table 3.

Effect of LPS (10 mg/kg intraperitoneally) without or with dexamethasone (10 mg/kg intraperitoneally) on renal tissue cytokine concentrationsa

Sole dexamethasone administration showed no differences in the expression of renal sodium transporters compared with control level (Figure 1). Mice that were treated with LPS plus dexamethasone still revealed a significant downregulation of sodium transporter gene expression; however, concomitant injection of dexamethasone substantially attenuated the LPS-induced suppression of NHE3, ROMK, NKCC2, ENaC, and Na+/K+-ATPase gene expression and tended to result in abolishing the suppressive effect of LPS on renal sodium transporters 24 h after LPS injection (Figure 1). Also on the protein level, the positive effect of additional dexamethasone treatment on sodium transporter membrane protein is markedly noticeable in comparison with sole LPS injection (Figure 5).

Figure 5.
Figure 5.

Effect of LPS (10 mg/kg), dexamethasone (10 mg/kg), and the combination of both on ROMK, ENaC, Na+/K+-ATPase, and NHE3 protein in the kidney 24 h after intraperitoneal injection. Representative immunoblot of ROMK; ENaC-α, -β, and -γ; Na+/K+-ATPase; and NHE3 protein. The anti-ROMK antibody recognized a band of 97 kD, and anti-NHE3 antibody and anti–ENaC-β and anti–ENaC-γ antibody recognized a band of 90 kD. The anti–Na+/K+-ATPase antibody detected a band of 110 kD and anti–ENaC-α bands of 83 and 90 kD. Values are related to signals that were obtained for β-actin protein and given as percentage of vehicle control. Data are means ± SEM of six mice per group. *P < 0.05 versus control; #P < 0.05 versus LPS.

Effect of Low-Dosage LPS on Hemodynamic/Renal Parameters and on Sodium Transporter Expression

Mice were administered injections of low-dosage LPS as a model for inflammation without arterial hypotension and renal ischemia. Twelve hours after injection of both 1 and 5 mg/kg LPS, renal tissue cytokine concentrations increased but mice remained normotensive. However, low-dosage LPS was sufficient enough to decrease renal parameters and expression of renal sodium transporters (Figure 6, Table 4).

Figure 6.
Figure 6.

Effect of LPS (1, 5, and 10 mg/kg) on mean arterial pressure (MAP) and tubular sodium reabsorption (A); the expression of ROMK, NKCC2, ENaC, Na+/K+-ATPase α1, and NHE3 mRNA in the kidney (B); and cytokine concentration in renal tissue (pg/mg protein; C) 12 h after intraperitoneal injection. Values of MAP and tubular sodium reabsorption are related to data of control mice and given as percentage of vehicle control. Values of sodium transporters are related to signals that were obtained for β-actin mRNA and given as percentage of vehicle control. Data are means ± SEM of six mice per group. *P < 0.05 versus control.

View this table:
Table 4.

Effect of low-dosage LPS (1 and 5 mg/kg intraperitoneally) on hemodynamic, blood, and renal parameters 12 h after injectiona

Effect of Renal Hypoperfusion and Ischemia-Reperfusion on Sodium Transporter Expression and Tissue Cytokine Concentration

Clipping of the left renal artery resulted in a renal hypoperfusion with decreased renocortical tissue perfusion to approximately 40% of control level, which is comparable to values of septic animals (19). Renal hypoperfusion did not change gene expression of tubular sodium transporters compared with sham-operated animals 6, 12, and 24 h after clipping. In contrast, ischemia-reperfusion significantly decreased mRNA levels of renal sodium transporters. Neither renal clipping nor ischemia-reperfusion affected expression of β-actin. Renal tissue concentrations of IL-1β, TNF-α, and IFN-γ were not influenced after renal hypoperfusion but were elevated after renal ischemia-reperfusion compared with sham-treated mice 6, 12, and 24 h after operation (Figure 7).

Figure 7.
Figure 7.

Effect of renal hypoperfusion (A) and renal ischemia-reperfusion (B) on the expression of ROMK, NKCC2, ENaC, Na+/K+-ATPase α1, and NHE3 mRNA and on renal cortical tissue perfusion 6, 12, and 24 h after surgery. Values of renocortical perfusion are given as percentage of sham treatment. Values of renal sodium transporters are related to signals that were obtained for β-actin mRNA and given as percentage of sham treatment. (C) Renal tissue concentration of proinflammatory cytokines (pg/mg protein) 6, 12, and 24 h after sham treatment, renal hypoperfusion, and renal ischemia-reperfusion. Data are means ± SEM of six mice per group. *P < 0.05 versus sham treatment. n.d., not detectable.

Effect of Cytokines on Sodium Transporter Expression in CCD Cells

As hypothesized and already demonstrated in vivo, the proinflammatory cytokines IL-1β, TNF-α, and IFN-γ downregulated expression of ROMK, ENaC, and Na+/K+-ATPase in murine CCD cells. This underlines our assumption that cytokines mediate the downregulative effect of LPS on renal sodium transporters also in the absence of ischemia (Figure 8). LPS, cytokines, and dexamethasone had no effect on expression of β-actin gene or protein.

Figure 8.
Figure 8.

Effect of proinflammatory cytokines (IL-1β, TNF-α, and IFN-γ, each 100 ng/ml) on the expression of ROMK, ENaC, and Na+/K+-ATPase mRNA in cortical collecting duct cells 12 h after exposition. Values are related to signals that were obtained for β-actin mRNA and given as percentage of vehicle control. Data are means ± SEM of six wells per group. *P < 0.05 versus control.

Discussion

The pathophysiology of sepsis-associated renal tubular dysfunction with impaired urinary concentration and increased fractional sodium excretion is only poorly understood. Adequate tubular function with the ability of potent urinary concentration and sodium reabsorption depends on the functional expression of several tubular transporters, such as ROMK, NKCC2, ENaC, Na+/K+-ATPase, and NHE3 (27). Therefore, we aimed to characterize the regulation of these transporters during severe experimental inflammation.

As an in vivo model for experimental inflammation, we used the intraperitoneal injection of LPS, an established, easy-to-apply maneuver with a low dispersion and mortality rates like the peritonitis models of sepsis (28). However, limitations such as overwhelming, short-lived LPS reactions are not rejectable (28). In our study, LPS treatment caused a time-dependent pronounced arterial hypotension that was associated with tachycardia and ARF with reduced GFR, indicating the validity of our sepsis model. Fractional sodium excretion and tubular sodium reabsorption, both indicators of tubular function in this study, decreased after LPS injection, indicating tubular damage, which is in accordance with previous findings (29,30). Noteworthy, it has been shown that LPS infusion had an immediate antinatriuretic effect in the first hours after injection, leading subsequently to a marked increase in fractional sodium excretion, suggesting a delayed LPS-induced impairment in tubular sodium reabsorption and therefore confirming our results (31).

In this study, depressed renal tubular function is accompanied by a marked downregulation of ROMK, NKCC2, ENaC, Na+/K+-ATPase, and NHE3, denoting a possible causal linkage between impairment of renal sodium reabsorption and expression of these transporters. This hypothesis is strengthened by studies that described the coexistence of renal tubular dysfunction and downregulation of tubular sodium transporters, especially NHE3, Na+/K+-ATPase, and NKCC2 after renal ischemia-reperfusion (32–35). Because hypernatremia was observed in mice that were treated with LPS, one could assume that high sodium plasma levels influence expression of sodium transporters. However, in a previous study, hypernatremia did not affect expression of tubular sodium transporters (36).

We were further interested in the mechanisms and pathways along which septic conditions lead to downregulation of tubular sodium transporters. The hallmark of sepsis is the potent induction of proinflammatory cytokines such as TNF-α, IL-1β, or IFN-γ (26). Therefore, we were interested in the effect of these mediators on functional renal and hemodynamic parameters and on the expression of renal sodium transporters. Similar to LPS, injection of IL-1β caused a significant depression of hemodynamic and renal function. In addition, we found that IL-1β, TNF-α, and especially the combination of both extensively downregulated expression of ROMK, NKCC2, ENaC, Na+/K+-ATPase, and NHE3, whereas IFN-γ only partially inhibited expression of these transporters. We conclude that cytokines possibly mediate LPS-induced downregulation of tubular sodium transporters.

To test this hypothesis further, we performed experiments with knockout mice that had a deficiency for TNF-α, IL-1R1, or IFN-γ. However, it turned out that the absence of single-cytokine effects does not prevent LPS-induced downregulation of tubular sodium transporters, suggesting that LPS-induced inhibition of sodium transporter gene expression cannot be attributed to single cytokines likely because of the overlapping interactions of several proinflammatory cytokines. These experimental in vivo results are in accordance with results of clinical trials that reported no beneficial effects of anti–single-cytokine strategies in patients with sepsis (37–39).

Therefore, we performed experiments with mice that were administered injections of glucocorticoid to reduce LPS-induced upregulation of several proinflammatory cytokines. Indeed, we found that expanded inhibition of the induction of proinflammatory cytokines by glucocorticoid treatment attenuated LPS-induced downregulation of all sodium transporters. In accordance with previous data (40), glucocorticoid treatment alleviated the effect of LPS on renal function. These results emphasize the possible impact of proinflammatory cytokines in the pathogenesis of sepsis-induced ARF with tubular dysfunction and downregulation of renal sodium transporters.

Because renal ischemia is potentially present in septic ARF with cardiovascular depression (19,28,30,31) and because downregulation of several tubular sodium transporters has been demonstrated after renal ischemia-reperfusion injury (32–35), one could assume that the effects that were observed in this study may be due to renal ischemia that resulted from systemic hypotension. To clarify the role of systemic hypotension and renal ischemia in the regulation of renal sodium transporter expression, we performed several additional experiments.

First, we investigated the effect of inflammation in the absence of hypotension and renal ischemia on the expression of renal sodium transporters. We used low-dosage LPS, which caused an increase in proinflammatory cytokines in renal tissue without systemic hypotension. Mice that were administered injections of low-dosage LPS showed impaired renal function and expression of renal sodium transporters, supporting our hypothesis that proinflammatory cytokines also in the absence of renal ischemia account for downregulation of renal sodium transporters under septic conditions. This is in line with previous trials that reported alleviated renal parameters and elevated TNF-α concentration under normotensive conditions after low-dosage LPS treatment, which could be diminished by supplementary injection of TNF neutralizers (22–24). For completeness, it should be mentioned that in a previous study, immunoblotting of rat kidney homogenates revealed an increased expression of NKCC2 protein after low-dosage LPS injection. However, this must not conflict with our results, because in this trial, mice showed antinatriuresis to the point of kidney extraction, leading subsequently to an increase in fractional sodium excretion, which indicates a delayed LPS-induced impact on renal function and sodium transporters in that study (31).

Second, we determined the impact of renal hypoperfusion on the expression of renal sodium transporters. We chose the renal artery clipping model, which decreases renocortical tissue perfusion to 40% of controls and is comparable to values of septic animals (19). In this model of renal hypoperfusion, expression of renal sodium transporters was not influenced compared with sham-clipped mice. In addition, renal tissue cytokine concentrations were unchanged after renal clipping in our and previous investigations (41,42). We conclude that renal hypoperfusion plays a minor role in mediating the downregulation of tubular sodium transporters during severe inflammation.

Third, we investigated the effect of renal ischemia-reperfusion on tubular sodium transporter expression. As already demonstrated by others (32–35), also in this study, renal ischemia-reperfusion led to decreased expression of renal sodium transporters, suggesting that ischemia is involved in the regulation of renal sodium transporter expression. However, the ischemia-reperfusion model is limited for imitating sepsis-induced renal ischemia, because ischemia-reperfusion means a complete renal artery occlusion followed by reperfusion, which contrasts to the prolonged renal hypoperfusion under septic circumstances (19). It must be clearly stated that in a complex in vivo model of severe inflammation, one cannot completely exclude the possible presence and influence of renal hypoperfusion followed by reperfusion on the expression of renal transporters.

In the end, to analyze the specific and independent impact of proinflammatory cytokines on the expression of renal sodium transporters in a model that completely excluded a possible hypotensive and ischemic effect, we performed in vitro experiments with murine CCD cells that expressed ROMK, ENaC, and Na+/K+-ATPase transporters (43–46). Proinflammatory cytokines suppressed the expression of ROMK, ENaC, and Na+/K+-ATPase, underlining our assumption that cytokines primarily account for the LPS-induced alteration on renal sodium transporters. This is in accordance with previous findings of cytokine-mediated inhibition of sodium reabsorption (47–49) and decreased expression of the Na+/K+-ATPase (50,51) in CCD cells.

Conclusion

Our data demonstrate that tubular sodium transporters are downregulated during severe experimental sepsis and suggest that proinflammatory cytokines are relevant in mediating regulation of renal sodium transporters during sepsis. Because of overlapping actions of different proinflammatory cytokines, downregulation of sodium transporters cannot be attributed to single cytokines, providing an explanation for why anti–single-cytokine strategies did not improve the outcome of patients with sepsis (37–39). In addition, our findings contribute to the explanation and understanding of the beneficial effects of glucocorticoids on the outcome of patients with sepsis (52–55).

Disclosures

None.

Acknowledgments

This study was financially supported by grants from the German Research Foundation (SFB 699).

The technical assistance provided by Maria Hirblinger is gratefully acknowledged.

Footnotes

  • Published online ahead of print. Publication date available at www.jasn.org.

References

  1. ↵
    Brivet FG, Kleinknecht DJ, Loirat P, Landais PJ: Acute renal failure in intensive care units: Causes, outcome, and prognostic factors of hospital mortality; a prospective, multicenter study. French Study Group on Acute Renal Failure. Crit Care Med 24 : 192 –198, 1996
    OpenUrlCrossRefPubMed
  2. ↵
    Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP: The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 273 : 117 –123, 1995
    OpenUrlCrossRefPubMed
  3. ↵
    Knepper MA, Kim GH, Fernandez-Llama P, Ecelbarger CA: Regulation of thick ascending limb transport by vasopressin. J Am Soc Nephrol 10 : 628 –634, 1999
    OpenUrlFREE Full Text
  4. ↵
    Kim GH, Ecelbarger CA, Mitchell C, Packer RK, Wade JB, Knepper MA: Vasopressin increases Na-K-2Cl cotransporter expression in thick ascending limb of Henle's loop. Am J Physiol 276 : F96 –F103, 1999
  5. ↵
    Frindt G, Palmer LG: Low-conductance K channels in apical membrane of rat cortical collecting tubule. Am J Physiol 256 : F143 –F151, 1989
  6. Greger R: Ion transport mechanisms in thick ascending limb of Henle's loop of mammalian nephron. Physiol Rev 65 : 760 –797, 1985
    OpenUrlPubMed
  7. Nusing RM, Pantalone F, Grone HJ, Seyberth HW, Wegmann M: Expression of the potassium channel ROMK in adult and fetal human kidney. Histochem Cell Biol 123 : 553 –559, 2005
    OpenUrlCrossRefPubMed
  8. ↵
    Wang WH: Two types of K+ channel in thick ascending limb of rat kidney. Am J Physiol 267 : F599 –F605, 1994
  9. ↵
    Canessa CM, Schild L, Buell G, Thorens B, Gautschi I, Horisberger JD, Rossier BC: Amiloride-sensitive epithelial Na+ channel is made of three homologous subunits. Nature 367 : 463 –467, 1994
    OpenUrlCrossRefPubMed
  10. ↵
    Sauter D, Fernandes S, Goncalves-Mendes N, Boulkroun S, Bankir L, Loffing J, Bouby N: Long-term effects of vasopressin on the subcellular localization of ENaC in the renal collecting system. Kidney Int 69 : 1024 –1032, 2006
    OpenUrlCrossRefPubMed
  11. ↵
    Grinevich V, Knepper MA, Verbalis J, Reyes I, Aguilera G: Acute endotoxemia in rats induces down-regulation of V2 vasopressin receptors and aquaporin-2 content in the kidney medulla. Kidney Int 65 : 54 –62, 2004
    OpenUrlCrossRefPubMed
  12. ↵
    Bucher M, Hobbhahn J, Kurtz A: Nitric oxide-dependent down-regulation of angiotensin II type 2 receptors during experimental sepsis. Crit Care Med 29 : 1750 –1755, 2001
    OpenUrlCrossRefPubMed
  13. Bucher M, Hobbhahn J, Taeger K, Kurtz A: Cytokine-mediated downregulation of vasopressin V(1A) receptors during acute endotoxemia in rats. Am J Physiol Regul Integr Comp Physiol 282 : R979 –R984, 2002
    OpenUrlCrossRefPubMed
  14. Bucher M, Ittner KP, Hobbhahn J, Taeger K, Kurtz A: Downregulation of angiotensin II type 1 receptors during sepsis. Hypertension 38 : 177 –182, 2001
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Bucher M, Kees F, Taeger K, Kurtz A: Cytokines down-regulate alpha1-adrenergic receptor expression during endotoxemia. Crit Care Med 31 : 566 –571, 2003
    OpenUrlCrossRefPubMed
  16. ↵
    Briegel J, Jochum M, Gippner-Steppert C, Thiel M: Immunomodulation in septic shock: Hydrocortisone differentially regulates cytokine responses. J Am Soc Nephrol 12[Suppl 17] : S70 –S74, 2001
  17. Keh D, Boehnke T, Weber-Cartens S, Schulz C, Ahlers O, Bercker S, Volk HD, Doecke WD, Falke KJ, Gerlach H: Immunologic and hemodynamic effects of “low-dose” hydrocortisone in septic shock: A double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med 167 : 512 –520, 2003
    OpenUrlCrossRefPubMed
  18. ↵
    Kiku Y, Matsuzawa H, Ohtsuka H, Terasaki N, Fukuda S, Kon-Nai S, Koiwa M, Yokomizo Y, Sato H, Rosol TJ, Okada H, Yoshino TO: Effects of chlorpromazine, pentoxifylline and dexamethasone on mRNA expression of lipopolysaccharide-induced inflammatory cytokines in bovine peripheral blood mononuclear cells. J Vet Med Sci 64 : 723 –726, 2002
    OpenUrlCrossRefPubMed
  19. ↵
    Millar CG, Thiemermann C: Carboxy-PTIO, a scavenger of nitric oxide, selectively inhibits the increase in medullary perfusion and improves renal function in endotoxemia. Shock 18 : 64 –68, 2002
    OpenUrlCrossRefPubMed
  20. ↵
    Nin N, Penuelas O, de Paula M, Lorente JA, Fernandez-Segoviano P, Esteban A: Ventilation-induced lung injury in rats is associated with organ injury and systemic inflammation that is attenuated by dexamethasone. Crit Care Med 34 : 1093 –1098, 2006
    OpenUrlCrossRefPubMed
  21. Van Molle W, Hochepied T, Brouckaert P, Libert C: The major acute-phase protein, serum amyloid P component, in mice is not involved in endogenous resistance against tumor necrosis factor alpha-induced lethal hepatitis, shock, and skin necrosis. Infect Immun 68 : 5026 –5029, 2000
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Knotek M, Rogachev B, Wang W, Ecder T, Melnikov V, Gengaro PE, Esson M, Edelstein CL, Dinarello CA, Schrier RW: Endotoxemic renal failure in mice: Role of tumor necrosis factor independent of inducible nitric oxide synthase. Kidney Int 59 : 2243 –2249, 2001
    OpenUrlCrossRefPubMed
  23. Wang W, Jittikanont S, Falk SA, Li P, Feng L, Gengaro PE, Poole BD, Bowler RP, Day BJ, Crapo JD, Schrier RW: Interaction among nitric oxide, reactive oxygen species, and antioxidants during endotoxemia-related acute renal failure. Am J Physiol Renal Physiol 284 : F532 –F537, 2003
    OpenUrlCrossRefPubMed
  24. ↵
    Wang W, Zolty E, Falk S, Basava V, Reznikov L, Schrier RW: Pentoxifylline protects against endotoxin-induced acute renal failure in mice. Am J Physiol Renal Physiol 291 : F1090 –F1095, 2006
    OpenUrlCrossRefPubMed
  25. ↵
    Berger S, Bleich M, Schmid W, Cole TJ, Peters J, Watanabe H, Kriz W, Warth R, Greger R, Schutz G: Mineralocorticoid receptor knockout mice: Pathophysiology of Na+ metabolism. Proc Natl Acad Sci U S A 95 : 9424 –9429, 1998
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Parrillo JE: Pathogenetic mechanisms of septic shock. N Engl J Med 328 : 1471 –1477, 1993
    OpenUrlCrossRefPubMed
  27. ↵
    Lang F, Capasso G, Schwab M, Waldegger S: Renal tubular transport and the genetic basis of hypertensive disease. Clin Exp Nephrol 9 : 91 –99, 2005
    OpenUrlCrossRefPubMed
  28. ↵
    Parker SJ, Watkins PE: Experimental models of gram-negative sepsis. Br J Surg 88 : 22 –30, 2001
    OpenUrlCrossRefPubMed
  29. ↵
    Edremitlioglu M, Kilic D, Oter S, Kisa U, Korkmaz A, Coskun O, Bedir O: The effect of hyperbaric oxygen treatment on the renal functions in septic rats: Relation to oxidative damage. Surg Today 35 : 653 –661, 2005
    OpenUrlCrossRefPubMed
  30. ↵
    Schramm L, Weierich T, Heldbreder E, Zimmermann J, Netzer KO, Wanner C: Endotoxin-induced acute renal failure in rats: Effects of L-arginine and nitric oxide synthase inhibition on renal function. J Nephrol 18 : 374 –381, 2005
    OpenUrlPubMed
  31. ↵
    Jonassen TE, Graebe M, Promeneur D, Nielsen S, Christensen S, Olsen NV: Lipopolysaccharide-induced acute renal failure in conscious rats: Effects of specific phosphodiesterase type 3 and 4 inhibition. J Pharmacol Exp Ther 303 : 364 –374, 2002
    OpenUrlAbstract/FREE Full Text
  32. ↵
    Fernandez-Llama P, Andrews P, Turner R, Saggi S, Dimari J, Kwon TH, Nielsen S, Safirstein R, Knepper MA: Decreased abundance of collecting duct aquaporins in post-ischemic renal failure in rats. J Am Soc Nephrol 10 : 1658 –1668, 1999
    OpenUrlAbstract/FREE Full Text
  33. Kwon TH, Frokiaer J, Han JS, Knepper MA, Nielsen S: Decreased abundance of major Na(+) transporters in kidneys of rats with ischemia-induced acute renal failure. Am J Physiol Renal Physiol 278 : F925 –F939, 2000
    OpenUrlPubMed
  34. Van Why SK, Mann AS, Ardito T, Siegel NJ, Kashgarian M: Expression and molecular regulation of Na(+)-K(+)-ATPase after renal ischemia. Am J Physiol 267 : F75 –F85, 1994
  35. ↵
    Wang Z, Rabb H, Haq M, Shull GE, Soleimani M: A possible molecular basis of natriuresis during ischemic-reperfusion injury in the kidney. J Am Soc Nephrol 9 : 605 –613, 1998
    OpenUrlAbstract
  36. ↵
    Wolf K, Castrop H, Riegger GA, Kurtz A, Kramer BK: Differential gene regulation of renal salt entry pathways by salt load in the distal nephron of the rat. Pflugers Arch 442 : 498 –504, 2001
    OpenUrlCrossRefPubMed
  37. ↵
    Abraham E: Why immunomodulatory therapies have not worked in sepsis. Intensive Care Med 25 : 556 –566, 1999
    OpenUrlCrossRefPubMed
  38. Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Benjamin E: Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 334 : 1697 –1702, 1996
    OpenUrlCrossRefPubMed
  39. ↵
    Opal SM, Fisher CJ Jr, Dhainaut JF, Vincent JL, Brase R, Lowry SF, Sadoff JC, Slotman GJ, Levy H, Balk RA, Shelly MP, Pribble JP, LaBrecque JF, Lookabaugh J, Donovan H, Dubin H, Baughman R, Norman J, DeMaria E, Matzel K, Abraham E, Seneff M: Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 25 : 1115 –1124, 1997
    OpenUrlCrossRefPubMed
  40. ↵
    Tsao CM, Ho ST, Chen A, Wang JJ, Li CY, Tsai SK, Wu CC: Low-dose dexamethasone ameliorates circulatory failure and renal dysfunction in conscious rats with endotoxemia. Shock 21 : 484 –491, 2004
    OpenUrlCrossRefPubMed
  41. ↵
    Beaumont K, Vaughn DA, Casto R, Printz MP, Fanestil DD: Thiazide diuretic receptors in spontaneously hypertensive rats and 2-kidney 1-clip hypertensive rats. Clin Exp Hypertens A 12 : 215 –226, 1990
    OpenUrlPubMed
  42. ↵
    Yip KP, Tse CM, McDonough AA, Marsh DJ: Redistribution of Na+/H+ exchanger isoform NHE3 in proximal tubules induced by acute and chronic hypertension. Am J Physiol 275 : F565 –F575, 1998
  43. ↵
    Sun TJ, Zeng WZ, Huang CL: Inhibition of ROMK potassium channel by syntaxin 1A. Am J Physiol Renal Physiol 288 : F284 –F289, 2005
    OpenUrlCrossRefPubMed
  44. Yoo D, Kim BY, Campo C, Nance L, King A, Maouyo D, Welling PA: Cell surface expression of the ROMK (Kir 1.1) channel is regulated by the aldosterone-induced kinase, SGK-1, and protein kinase A. J Biol Chem 278 : 23066 –23075, 2003
    OpenUrlAbstract/FREE Full Text
  45. Butterworth MB, Edinger RS, Johnson JP, Frizzell RA: Acute ENaC stimulation by cAMP in a kidney cell line is mediated by exocytic insertion from a recycling channel pool. J Gen Physiol 125 : 81 –101, 2005
  46. ↵
    Summa V, Mordasini D, Roger F, Bens M, Martin PY, Vandewalle A, Verrey F, Feraille E: Short term effect of aldosterone on Na,K-ATPase cell surface expression in kidney collecting duct cells. J Biol Chem 276 : 47087 –47093, 2001
    OpenUrlAbstract/FREE Full Text
  47. ↵
    Garcia NH, Pomposiello SI, Garvin JL: Nitric oxide inhibits ADH-stimulated osmotic water permeability in cortical collecting ducts. Am J Physiol 270 : F206 –F210, 1996
  48. Sakairi Y, Ando Y, Tabei K, Kusano E, Asano Y: Interleukin-1 inhibits sodium and water transport in rabbit cortical collecting duct. Am J Physiol 266 : F674 –F680, 1994
  49. ↵
    Stoos BA, Carretero OA, Garvin JL: Endothelial-derived nitric oxide inhibits sodium transport by affecting apical membrane channels in cultured collecting duct cells. J Am Soc Nephrol 4 : 1855 –1860, 1994
    OpenUrlAbstract
  50. ↵
    Zeidel ML, Brady HR, Kohan DE: Interleukin-1 inhibition of Na(+)-K(+)-ATPase in inner medullary collecting duct cells: Role of PGE2. Am J Physiol 261 : F1013 –F1016, 1991
  51. ↵
    Kohan DE: Interleukin-1 regulation of collecting duct prostaglandin E2 and cyclic nucleotide accumulation. J Lab Clin Med 123 : 668 –675, 1994
    OpenUrlPubMed
  52. ↵
    Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y: Corticosteroids for treating severe sepsis and septic shock. Cochrane Database Syst Rev ( 1) : CD002243, 2004
  53. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troche G, Chaumet-Riffaut P, Bellissant E: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288 : 862 –871, 2002
    OpenUrlCrossRefPubMed
  54. Briegel J, Forst H, Haller M, Schelling G, Kilger E, Kuprat G, Hemmer B, Hummel T, Lenhart A, Heyduck M, Stoll C, Peter K: Stress doses of hydrocortisone reverse hyperdynamic septic shock: A prospective, randomized, double-blind, single-center study. Crit Care Med 27 : 723 –732, 1999
    OpenUrlCrossRefPubMed
  55. ↵
    Kilger E, Weis F, Briegel J, Frey L, Goetz AE, Reuter D, Nagy A, Schuetz A, Lamm P, Knoll A, Peter K: Stress doses of hydrocortisone reduce severe systemic inflammatory response syndrome and improve early outcome in a risk group of patients after cardiac surgery. Crit Care Med 31 : 1068 –1074, 2003
    OpenUrlCrossRefPubMed
Back to top

In this issue

View Selected Citations (0)
Print
Download PDF
Email Article
Citation Tools
Request Permissions
Regulation of Renal Sodium Transporters during Severe Inflammation
Christoph Schmidt, Klaus Höcherl, Frank Schweda, Armin Kurtz, Michael Bucher
JASN Apr 2007, 18 (4) 1072-1083; DOI: 10.1681/ASN.2006050454
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section